Tinlarebant

Belite Bio Inc (BLTE) is advancing Tinlarebant, a novel oral tablet for Stargardt Disease (STGD1) and Geographic Atrophy (GA), targeting RBP4 to reduce harmful retinal by-products. Global phase III trials (DRAGON and DRAGON II) are ongoing, with interim results expected by early 2025. BLTE's stock has shown significant volatility.

In 2024, Modern Retina highlighted advancements in treating AMD and GA, technology aiding AMD patients, social factors affecting ophthalmology treatment access, progress in inherited retinal diseases research, safety during the total solar eclipse, and key discussions from the ASRS 2024 Annual Meeting.

In 2024, Modern Retina highlighted advancements in treating AMD and GA, technology aiding AMD patients, social factors affecting diabetic retinopathy treatment, progress in inherited retinal diseases research, safety during the total solar eclipse, and key discussions from the ASRS 2024 Annual Meeting.

In 2024, Modern Retina highlighted advancements in ophthalmology, focusing on AMD and GA treatments, technology aiding AMD patients, social factors affecting diabetic retinopathy treatment, inherited retinal diseases research, safety during the total solar eclipse, and key discussions from the ASRS 2024 Annual Meeting.

Belite Bio announced financial results for Q3 2024, progress in Tinlarebant trials for Stargardt disease and geographic atrophy, appointment of Dr. Hendrik P.N. Scholl as CMO, and an anticipated interim analysis for the DRAGON trial by end of 2024 or early 2025.

The 2024 American Academy of Ophthalmology meeting in Chicago will feature presentations on clinical trial data from Alkeus Pharmaceuticals, Annexon, Inc., Atsena Therapeutics, Avirmax Biopharma, Inc., Beacon Therapeutics, Belite Bio, Eyenovia, LENZ Therapeutics, Nanoscope Therapeutics, Inc., and ZEISS Medical Technology.

Belite Bio to present Phase II Stargardt disease trial data at AAO 2024, featuring Tinlarebant (LBS-008), an oral therapy reducing vitamin A-based toxins in retinal diseases like STGD1 and geographic atrophy.